ArticleFrontiers in bioengineering and biotechnology2020
Biosafety Measures, Socio-Economic Impacts and Challenges of Bt-brinjal Cultivation in Bangladesh.
Article in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 8 citations in OpenAlex.
- Impact of genetically modified Brinjal (Bt brinjal) on farmers' income and production in Pabna District, Bangladesh.GM crops & food · 2025Article
- Farmers' intention to continue Bt brinjal adoption in Bangladesh: pre and post-adoption drivers.Transgenic research · 2025Article
- Biosafety status analysis and risk assessment of laboratories from 2021 to 2023 in Jiaxing, China.Frontiers in bioengineering and biotechnology · 2025Article
- Pest risk assessment ofEFSA journal. European Food Safety Authority · 2024Article
- Understanding public perspectives on genetically engineered Brinjal and the adoption of modern biotechnology in Bangladesh.Frontiers in bioengineering and biotechnology · 2024Article
- Public perception of plant gene technologies worldwide in the light of food security.GM crops & food · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study surveyed the onsite biosafety measures adopted by the farmers cultivating Bt-brinjal, the socio-economic impact, and the challenges of Bt-brinjal cultivation in Bangladesh through interviews of 101 farmers from 26 Upazila (administrative region) under 20 Districts. Bt-brinjal 2, released by Bangladesh Agricultural Research Institute (BARI), is cultivated by 35% of the surveyed farmers. It was revealed that 52% of farmers maintained border crops. Among the growers, 52% informed that they disclose to the buyers that they are selling Bt-brinjal while selling in the open market where no product is traditionally labeled. Most of the farmers (71%) use Bt-brinjal plant debris as animal feed. Farmers (60%) received training on biosafety of Bt-brinjal cultivation. According to 85% of farmers, Bt-brinjal cultivation improved insect control. The farmers (77%) agreed that Bt-brinjal reduced labor and chemical costs and 75% of the farmers found increased yield and 72% of them found enhanced income by Bt-brinjal cultivation. However, 25% farmers informed that they did not get increased yield due to incidence of secondary insects. Most of the farmers (89%) perceive that cultivation of Bt-brinjal improved quality of brinjal. Furthermore, 59% of the farmers opined that price was reduced due to Bt-brinjal cultivation. The farmers also believe that Bt-brinjal cultivation reduced pesticide use (97%) and concern of insecticide use (96%) and hence they consider Bt-brinjal safer for human health (96%). However, to harvest the benefits of modern biotechnology, proper management of the biosafety in Bt-brinjal cultivation and labeling of Bt-brinjal during marketing should be maintained properly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.